On October 23, Novartis AG fell 3.7% in Regular Trading, trading at $150.0 per share, with turnover of $196 million.
The clearest catalyst was a same-day note indicating UBS downgraded Novartis AG to neutral, which pressured sentiment even as the company reported supportive six-year Kisqali data in early breast cancer.
That clinical update showed Kisqali plus endocrine therapy reduced the risk of death by 19.1% versus endocrine therapy alone in high-risk HR-positive, HER2-negative stage II and III early breast cancer, with an overall survival hazard ratio of 0.809 and invasive disease-free survival benefit widening to 5.3% at six years. Novartis AG also recently said the European Commission approved Cosentyx for polymyalgia rheumatica. Still, with third-quarter results due October 27 and prior commentary pointing to continued Entresto erosion after loss of exclusivity, the downgrade appears to have had stronger immediate market impact.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments